Nov 30th, 2018 - MORPHABOND ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Nov 30th, 2018 - ROXYBOND is an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
May 31st, 2018 - MORPHABOND ER is: A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough to require daily around-the clock, long-term treatment with an opioid, when other pain treatments such as non-opioid pain medicines or immediate-release opioid medicines do not treat your pain well enough or you cannot tolerate them.
Mar 31st, 2017 - ROXYBOND is: A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough to require an opioid pain medicine, when other pain treatments such as nonopioid pain medicines do not treat your pain well enough or you cannot tolerate them.
Oct 30th, 2015 - Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing MORPHABOND, and monitor all patients receiving MORPHABOND for development of these behaviors or conditions. ... Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed MORPHABOND.
Oct 30th, 2015 - ROXYBOND™ safely and effectively. See full prescribing information for ROXYBOND. ROXYBOND (oxycodone hydrochloride) tablets, for oral use, CII.
INDICATIONS AND USAGE. ACTIQ® oral transmucosal lozenge, CII is indicated for the management of breakthrough pain in cancer patients 16 years of age
BELBUCA® (Buprenorphine) is the first oral formulation of buprenorphine proven to deliver consistent analgesia and tolerability. Rethink Relief.
CASSIPA film contains buprenorphine, a partial‐opioid agonist, and naloxone, an opioid antagonist, and is indicated for the maintenance treatment of opioid dependence.
Information for prescribers about the organizations and Surgeon General advice to co-prescribe naloxone to patients who will have opioids. Also includes the Surgeon General’s speech on opioids and co-prescribing naloxone.
Discover Butrans, a Schedule III, extended-release opioid. See Full Prescribing Info, Safety Info & Boxed Warning.
Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products that contain alcohol while taking EMBEDA.
Information for physicians about an analgesic therapy that treats multiple sources of pain. Please see Full Prescribing Information and Important Safety Information.
Discover Hysingla ER Extended-Release Tablets CII, a non-APAP hydrocodone. See Full PI, Medication Guide & Boxed Warning.
LUCEMYRA (lofexidine), an oral tablet, is a central alpha 2-adrenergic agonist that reduces the release of norepinephrine to suppress the neurochemical surge that produces opioid withdrawal.
Kadian. The U.S. Prescribing Information in this product database represents the current product labeling information as of the date of the document. While every ...
AVINZA is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which ...
Prolonged use of PERCOCET during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise ...
OxyContin carries a Boxed Warning and contains oxycodone, a Schedule II controlled substance with an abuse potential similar to other Schedule II opioids.
Xtampza® ER (oxycodone) is an extended-release opioid with a proprietary abuse-deterrent technology indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.